Australia markets closed

Prothena Corp PLC (0PT.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
29.40+0.20 (+0.68%)
As of 08:03AM CET. Market open.
Full screen
Previous close29.20
Bid29.40 x 300000
Ask29.60 x 300000
Day's range29.40 - 29.40
52-week range29.20 - 71.00
Avg. volume3
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Reuters

    FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug success

    Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives. Clinical trials are underway or completed for at least seven Alzheimer’s vaccines designed to harness the immune system to rid the brain of the disease-related proteins beta amyloid or tau, a review of the U.S. government’s database found. The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis.

  • Zacks

    Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market

    Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.

  • Zacks

    Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike

    Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.